Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evotec is a leading drug discovery and development partner for the pharmaceutical and biotechnology industry.

Evotec: Data-Driven R&D Company Filing New IPO

German biotech Evotec SE (OTC: EVTCY) plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $9.2 billion.

Germany Based Evotec Sets Terms For $576M US IPO

HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares ("ADSs") representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission ("SEC"). Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs.

Evotec SE: Announces Launch of Public Offering of American Depositary Shares

9M 2021 REVENUES EXPECTED TO BE IN THE RANGE OF € 425 - 435 M ADJUSTED 9M 2021 EBITDA EXPECTED TO BE IN THE RANGE OF € 68 - 72 M THE FIGURES IN THIS ANNOUNCEMENT ARE PRELIMINARY AND SUBJECT TO CHANGE THE COMPLETE 9M 2021 INTERIM FINANCIAL RESULTS WILL BE RELEASED AS SCHEDULED ON 11 NOVEMBER 2021 HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), today reported preliminary and unaudited results for the first nine months ended 30 September 2021. Evotec expects revenues from contracts with customers for the first nine months of 2021 to be in the range of € 425 - 435 m; significantly above the € 360.4 m posted in the prior year's period.

Evotec Provides Preliminary Nine Month Financial Results

Pasithea Therapeutics Corp

-- Company contracts leading global drug development company to advance initial drug candidate -- -- Company contracts leading global drug development company to advance initial drug candidate --

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

HAMBURG, GERMANY / ACCESSWIRE / October 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares

Allstate

Roundhill Sports Betting & iGaming ETF

VanEck Vectors Gaming ETF

DraftKings

Global Eagle Entertainment

Las Vegas Sands

MGM Resorts

Rush Street Interactive

Sometimes a larger playing field is what it takes to score.

Here Are 2 Great Ways to Make an Investment in Online Betting Less Risky

DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTIONToronto, Ontario--(Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn's pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of...

Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead

The software and gambling company is the backbone behind many popular online casinos.

Is Evolution Gaming a Stock for the Long Haul?

HAMBURG, GERMANY / ACCESSWIRE / January 7, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021: J.P. Morgan 39th Annual Healthcare Conference 2021 Date: Monday, 11 January - Thursday, 14 January 2021             Presentation: Tuesday, 12 January, 7.30 am EST (1.30 pm CET, 12.30 pm GMT, 4.30 am PST) Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer Commerzbank German Investment Seminar Date: Wednesday, 13 January 2021 Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer UniCredit Kepler Cheuvreux German Corporate Conference Date: Wednesday, 20 January 2021             Presentation: Wednesday, 20 January, 12 pm CET Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer BioCapital Europe Date: Thursday, 11 March 2021 Venue: Virtual Attendee: Enno Spillner, Chief Financial Officer ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

Evotec To Attend Upcoming Investor Conferences

EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS' ATX-GX(TM) HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS HAMBURG, GERMANY / ACCESSWIRE / December 21, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Alloy Therapeutics ("Alloy"), a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec's antibody discovery platform. Under the terms of the agreement, Evotec receives access to Alloy's ATX-Gx(TM) mouse platform to enable best-in-class in vivo discovery of fully human monoclonal antibodies for use in both its proprietary as well as partnered R&D projects across more than 15 disease areas.

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

In an announcement on Thursday, Evotec (ETR: EVT) said that it has acquired the U.S-based biologics company Just Biotherapeutics. The U.S. company is financially backed by the Gates Foundation.

Evotec acquires U.S-based Just Biotherapeutics for £73.59 million

News for Evotec SE Stock (EVO)